Fresenius SE & Co. (OTCMKTS:FSNUY) Announces Quarterly Earnings Results

Fresenius SE & Co. (OTCMKTS:FSNUY) released its earnings results on Wednesday. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.22 by $0.03, Zacks reports. The firm had revenue of $6.52 billion for the quarter, compared to analyst estimates of $6.51 billion. Fresenius SE & Co. had a net margin of 6.58% and a return on equity of 10.24%.

Fresenius SE & Co. Stock Up 0.8%

OTCMKTS:FSNUY traded up $0.11 during trading hours on Friday, hitting $14.53. 35,308 shares of the company traded hands, compared to its average volume of 167,821. Fresenius SE & Co. has a one year low of $10.33 and a one year high of $15.94. The firm’s 50-day simple moving average is $12.93 and its 200-day simple moving average is $12.86. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.41. The company has a market cap of $32.74 billion, a PE ratio of 18.16 and a beta of 0.63.

Wall Street Analysts Forecast Growth

FSNUY has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, July 21st. Finally, Citigroup reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a report on Wednesday, October 28th. Three investment analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy”.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.